Treats insomnia characterized. ANDA 204170, held by Sun Pharm. Zolpidem Tartrate.
As of Nov 16, 2026, ANDA 204170 (Zolpidem Tartrate), held by Sun Pharm, was first approved by FDA on Jan 24, 2017, with 5 approved supplements and 0 published complete response letters.
Zolpidem tartrate extended-release tablets, USP are indicated for the short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 24, 2017 | Original application | Approved | None posted |
| Zolpidem Tartrate6.25MG · tablet, extended release;oral | Zolpidem Tartrate | Rx |
| Zolpidem Tartrate12.5MG · tablet, extended release;oral | Zolpidem Tartrate | Rx |
| Mar 8, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jan 24, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters